Subsequent integrative analysis of genomic and transcriptomic signatures has further characterised an ‘immunogenic’ subtype in PDAC 12, associated with a significant immune infiltrate, with predominant expression profiles related to infiltrating B and T cells, upregulation of CTLA4 and PD1 immunosuppressive pathways, suggesting that a proportion of PDAC tumours may potentially be targeted with immune‐modulating agents. The gene discussed is CTLA4; the disease is neoplasm.